News coverage about Blueprint Medicines (NASDAQ:BPMC) has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Blueprint Medicines earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.4448574220845 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the headlines that may have effected Accern Sentiment’s analysis:

Blueprint Medicines (BPMC) traded down $0.20 during midday trading on Friday, hitting $75.13. 1,349,318 shares of the company traded hands, compared to its average volume of 638,031. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.02. Blueprint Medicines has a twelve month low of $26.38 and a twelve month high of $92.00.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.06). The firm had revenue of $8.07 million for the quarter, compared to analyst estimates of $5.35 million. Blueprint Medicines had a negative return on equity of 43.11% and a negative net margin of 437.83%. The business’s revenue was up 31.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.62) EPS. equities analysts expect that Blueprint Medicines will post -3.75 EPS for the current year.

A number of brokerages recently commented on BPMC. Goldman Sachs Group upped their price target on shares of Blueprint Medicines from $82.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 11th. Raymond James Financial set a $82.00 target price on shares of Blueprint Medicines and gave the stock a “buy” rating in a research report on Sunday, December 10th. JMP Securities increased their target price on shares of Blueprint Medicines from $88.00 to $97.00 and gave the stock an “outperform” rating in a research report on Monday, December 11th. BidaskClub lowered shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. Finally, ValuEngine lowered shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $83.78.

In related news, CEO Jeffrey W. Albers sold 30,000 shares of the stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $70.31, for a total value of $2,109,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Daniel Lynch sold 2,500 shares of the stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $60.00, for a total transaction of $150,000.00. Following the completion of the transaction, the director now directly owns 209,342 shares of the company’s stock, valued at approximately $12,560,520. The disclosure for this sale can be found here. In the last three months, insiders sold 72,639 shares of company stock valued at $4,871,743. 3.40% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/12/17/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-blueprint-medicines-bpmc-share-price.html.

About Blueprint Medicines

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Stock Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related stocks with our FREE daily email newsletter.